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Abstract
Background: Precocious puberty (PP) is defined as premature pubertal development. Its consequences surpass the
physical evidence of sexual maturity with the premature epiphyseal closure of the long bones and the reduction of
adult stature by varied degrees. Central PP is characteristically dependent on GnRH and most of its causes are not
completely known. Altered estrogen action is also believed to be involved in the genesis of PP. In fact, estrogen
receptor alpha (Rea) gene polymorphisms may be associated with early age at menarche. The objective of this
study was to investigate the relationship between Reα gene polymorphisms (PvuII and XbaI) and the occurrence of
central PP.
Methods: A total of 73 girls with central PP and 101 girls with normal pubertal maturation were evaluated. Both
groups were genotyped for the PvuII (T/C) and XbaI (A/G) polymorphisms in the Reα gene.
Results: The frequency distribution of the XbaI (p = 0.28) and of the PvuII (p = 0.12) genotypes, as well as the XbaI
and PvuII allelic variants (p = 0.23 and p = 0.86, respectively), did not differ between the groups.
Conclusion: The PvuII and XbaI Rea gene polymorphisms do not appear to be related to development of central
PP.
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Background
Precocious puberty (PP) is characterized by premature
pubertal development, that is, by the onset of puberty
before 8 years of age. Such precociousness surpasses the
physical evidence of sexual maturity with the premature
epiphyseal closure of the long bones and the reduction
of adult stature by varied degrees. The incidence is ap-
proximately 20/10,000 in that age group [1].
In 50% of patients with PP of central origin, onset is be-
tween 6 to 7 years [2]. Central precocious puberty (CPP)
occurs more frequently in girls than in boys (approxi-
mately 20:1), and about 90% of the female cases are idio-
pathic (unknown cause) or constitutional (family heritage)
[1, 3, 4].
The cause of most CPP cases is still unknown. The
main determinant of the onset of puberty seems to be
genetic. In studies with twins, monozygotic twins were
shown to be in closer agreement with respect to bone
age, age at menarche, increased height, and pubertal de-
velopment than were dizygotic twins [5].
There are several hypotheses for the onset of PP involv-
ing neurotransmitters, peptides, and hormones [6–8].
However, little is known about the influence of estrogen
and its receptor on the premature activation of the
hypothalamic-hypophyseal-ovarian axis. In fact, estrogen
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administration to immature female rats 5 to 10 days old
led to pulsatile secretion of GnRH, typical of the process
of hypothalamic maturation. The secretion, in turn, led to
symptoms of PP [9]. Perhaps estrogen is not only a conse-
quence of the process of puberty onset in humans, but
also a contributory factor in the maturation of the
hypothalamic-hypophyseal-ovarian (HHO) axis via its re-
ceptor. This possibility has spurred a great deal of research
[10–12]. Polymorphisms have been reported in intron 1 of
the estrogen receptor gene, especially PvuII (REα-T397C)
and XbaI (REα-A351G) [13, 14]. Also, these polymor-
phisms are related to high risk of breast cancer and early
menarche [15–17]. In addition, those polymorphisms
seem to be the most prevalent and might interfere with
the estrogen effect. The meta-analysis of Korean and
China studies suggests that ESR1 XbaI and PvuII poly-
morphisms are associated with precocious puberty sus-
ceptibility [18]. However, there has not described these
polymorphisms on the precocious puberty in Brazilian
population yet. Therefore, our study aimed at determining
whether the polymorphisms which influence estrogen re-
ceptor activity were present at elevated frequency in girls
with PP.
Methods
Characteristics of the study population
This study was conducted at the Gynecology Division of
Childhood and Adolescence, Discipline of Gynecological
Endocrinology, Gynecology Department, São Paulo
Federal University – Paulista School of Medicine (UNI-
FESP-EPM). In the pre-selection phase, a medical history
was taken of the girls with the help of their guardians,
including clinical data, personal history, and family his-
tory. The girls underwent a clinical and a gynecological
examination. Inclusion criteria for the study group (73
girls) consisted of a previous or current diagnosis of PPP
corroborated by physical examination or medical re-
ports, and for the control group (104 girls), normal pu-
bertal development after 8 years of age. Exclusion
criteria were the presence of ovarian or adrenal neo-
plasms, the McCune-Albright syndrome, changes in the
central nervous system (tumors, congenital malforma-
tions, infections, and traumas), laboratory or clinical as-
sessment of hypothyroidism, use of hormones prior to
diagnosis and use of psychotropic drugs.
Extraction of genetic material and genotyping
DNA was extracted from peripheral blood leukocytes
using standard procedures. The intron from the ESR1
gene was amplified by PCR using 50 ng of the genomic
DNA in a final reaction volume of 50 μl containing 5 μl
of buffer, 0.2 mM dNTPs (from each of the four deoxyri-
bonucleotides), 0.2 μM of each primer pair that spanned
the polymorphic regions, 2 mM MgSO4, and 1 U Plat-
inum® Taq DNA Polymerase High Fidelity (Invitrogen).
The reaction took place in the VERITI (Apllied Biosys-
tems) thermocycler, using the following cycle: preheating
(94 °C for 2 min), denaturing for 40 cycles (94 °C for
60 s), annealing (50 °C for 90 s), extending (72 °C for
180 s), and extending one more final time (72 °C for
7 min). The primers used were sense 5′- CTG CCA
CCC TAT CTG TAT CTT TTC CTA TTC TCC -3′ and
antisense 5′- TCT TTC TCT GCC ACC CTG GCG
TCG ATT ATC TGA -3′ [19].
After amplification, the PCR products were digested
by the PCR-RFLP (polymerase chain reaction-restriction
fragment length polymorphism) technique separately
with the restriction enzymes, with recognition of the fol-
lowing sequence: 5′...CAG ↓ CTG...3′ and 5′...T ↓
CTAGA...3′, respectively for Pvull and Xbal in a final
volume of 20 μl at 37 °C for 16 h, containing 6 U Pvull
and 5 U XbaI (Promega), 2 μl enzyme buffer, 0.2 μl BSA
(bovine serum albumin), and 17.3 μl PCR product.
Fragment analysis was performed in 1% agarose gel
Table 1 Polymorphisms, restriction enzymes, allelic variants,
andsize of DNA fragment generated by PCR-RFLP
Polymorphisms Enzymes Allelic variant Fragment size (bp)
REα − 351 A/G XbaI A (wild) 1374
G (mutant) 936 + 438
REα −397 T/C PvuII T(wild) 1374
C (mutant) 931 + 443
Table 2 Mean, standard deviation, and frequency distribution (%) of the participants’ characteristics
Control group (n = 101) Study group (n = 73) p
Ethnicity
Caucasian - n (%) 25 (24.75) 16 (21.9) 0.69
Non-Caucasian - n, % 75 (74.25) 57 (78.1)
Family historya - n, % 19 (18.81) 18 (24.65) 0.34
Mother’s menarche (months) - mean ± SD 149.1 ± 16.78 143.1 ± 17.23 0.43
BMI - mean ± SD 20.9 ± 3.67 21.2 ± 4.99 0.85
afamily history of precocious puberty, n number of participants, SD standard deviation
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stained with ethidium bromide, and the bands were sep-
arated and photographed under ultraviolet light. The
PCR and RFLP conditions utilized followed the protocol
of Souza et al. [16, 17]. The restriction enzymes and the
base pair (bp) sizes for the normal and variant alleles are
summarized in Table 1. We excluded three participants
of control group due to problems with the blood
collection. The final number is 101 girls in this group.
We included the database in the supplemental files
(Additional file 1).
Statistical analysis
The data collection was followed by calculation of the
mean and standard deviation of the mean. The results
were shown as mean ± standard error of the mean.
When two groups were compared and the variables were
qualitative, the Fischer exact test was used, and when
the variables were quantitative, the Student t test was
applied. For polymorphisms, the Hardy-Weinberg (H-
W) equilibrium was calculated. The Power Calculation
of 80% was 70 patients per group based on the early me-
narche age frequency of Pvull/Xbal and high risk of
breast cancer [16, 17]. The analyses were carried out
with the SPSS version 16.0 software. All of the tests had
the rejection level of the null hypothesis set at 0.05 or
5% (p < 0.05).
Results
The main features of the study population and the fre-
quencies of the different genotypes are displayed in
Table 2. There was no significant difference between the
control group (101 girls) and the study group (73 girls)
with respect to the proportion of White and non-White
girls (p = 0.69), the percentage of ancestors with CPP, or
the mother’s age at menarche (control group: 149.1 ± 16.
78 months and study group: 143.1 ± 174.23 months).
Both groups had the same mean of body mass index
(BMI) (control group: 20.9 ± 3.67 and study group: 21.2
± 4.99); however, the percentage of obese patients
(BMI > 30) was higher in the control group (6 cases)
than in the study group (2 cases).
There was no difference between the two groups in the
distribution of the XbaI (p = 0.28) or the PvuII (p = 0.12)
genotypes, nor in the frequency of the XbaI (p = 0.23) or
PvuII (p = 0.86) allelic variants (Additional file 1, Tables 3
and 4).
The heterologous genotypes, A,G and T,C for Xbal
and Pvull, respectively, were the most frequent geno-
types detected in both the study and control groups.
The most frequent allele for the Xbal polymorphism
in each group was the G allele, which was not associ-
ated with an increased risk (OR:0.86 [95% CI = 0.51;
156]) for PP (p = 0.23). The most frequent allele for
the PvuII polymorphism in each group was the C
allele, which was similar in both groups. The control
group of Xbal was not consistent with with Hardy-
Weinberg equilibrium.
The estimating haplotypes of both polymorphisms and
their frequency differences of these between control
group and study group are on Table 5.
Figures 1 and 2 show the PCR-RFLP reactions for Xbal
and PvuII in a representative sample of the study
participants.
Discussion
It is still unclear what causes central precocious puberty
[20]. There is an intense, ongoing debate about the in-
volved mechanisms. Each individual’s genetic susceptibil-
ity, including polymorphisms, and the interaction of
environmental and nutritional factors, are deemed im-
portant factors at puberty onset [21]. However, so far no
consensus has been reached as to which of these deter-
minants is the most important. This point should be em-
phasized to make it obvious why further research is
needed. Our study aimed at evaluating the relationship
Table 3 Frequency distribution of the genotypes and Alleles of
the XbaI polymorphism in patients with precocious puberty and
normal puberty
Genotypes1 Control group (n = 101)* Study group (n = 73)
AA - n (%) 15 (14.85) 12 (16.40)
AG - n (%) 69 (68,32) 33 (45.20)
GG - n (%) 17 (16.83) 28 (38.40)
Alleles2
A – n** (%) 84 (49.41) 45 (42.45)
G – n** (%) 86 (50.59) 61 (57.55)
Total – n** (%) 170 (100) 106 (100)
1p = 0.28, n number of participants, * = control group is not consistent with
Hardy-Weinberg equilibrium; 2p = 0.23; n** = number of participants with
specific alleles
Table 4 Frequency distribution of the genotypes of the PvuII
polymorphism in patients with precocious puberty and normal
puberty
Genotypes1 Control group (n = 101) Study group (n = 73)
TT – n (%) 22 (21.78) 10 (13.69)
TC – n (%) 53 (52.48) 46 (63.02)
CC – n (%) 26 (25.74) 17 (23.29)
Alleles2
T - n** (%) 75 (48.70) 56 (47.06)
C - n** (%) 79 (51.30) 63 (52.94)
Total - n** (%) 154 (100) 119 (100)
1p = 0.12; n number of participants; 2p = 0.86; n** = number of participants
with specific alleles
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between precocious puberty and estrogen receptor poly-
morphisms in Brazilian population. However, no associ-
ation was found.
Epidemiologic studies report that many patients with
central precocious puberty had a family history positive for
this condition [22], thus suggesting a genetic inheritance. In
our study, those with a family history of precocious puberty
were only at a 2% greater risk of developing precocious
puberty than were the girls who had no such history. It
may be that the small number of girls with a positive family
history in our study influenced the negative findings.
Most of the studies assessing the influence of genetic
factors on puberty onset have attempted to correlate
them with central factors [7, 23–25]. Few studies have
evaluated the peripheral component as the trigger for
precocious puberty [9]. According to Gorai et al. [10],
estrogen is possibly the determinant in the maturation
of the HHO axis, but we did not found the association
of estrogen receptor polymorphism and central PP.
In different studies, the Reα gene polymorphisms have
been associated with several pathological conditions,
such as breast cancer, prostate cancer, osteoporosis,
endometriosis, and cardiovascular diseases [26–28]. Parl
et al. [29] found that the recessive mutant genotype of
the PvuII polymorphism was more abundant in women
with breast cancer, which is related to estrogen action.
However, few researchers have assessed these genes in
connection with age at menarche. Stavrou et al. [19] found
that individuals with a wild-type genotype seemed to have
a slightly delayed age at menarche. In our study, the same
genotypes were also associated with an age delay at me-
narche. Nevertheless, further studies are needed to pro-
duce conclusive results with respect to an association
between the PvuII polymorphism and puberty onset. A
delayed menarche is known to be a protection factor
against breast cancer and endometrial cancer, because it
reduces the exposure time of these tissues to estrogen.
Lee et al. [30] failed to show a connection between the
aforementioned polymorphisms and puberty onset and
progression in Korean girls, notwithstanding the more
homogeneous population sample. In addition, Luo et al.
[18] described a metanalysis with studies with Korean
and Chinese population and found that ESR1 XbaI and
PvuII polymorphisms are associated with precocious pu-
berty susceptibility. However, this revision there are
some bias, such some number of manuscript (n = 3) and
small samples in the studies. We did not found manu-
scripts with European and South America population to
compare our data. Besides, some authors suggest a
prevalence of precocious puberty among girls of African
descent [21]. Our results, however, drawn from a mixed
racial population characteristic of Brazil, did not show a
Table 5 Frequency distribution of the genotypes of the association between PvuII and Xbal polymorphisms in patients with
precocious puberty and normal puberty
Genotypes
associations
Control group (n = 101) Study group (n = 73)
AA + TT AA + TC AA + CC total AA + TT AA + TC AA + CC total
4 7 4 15 0 11 1 12
AG + TT AG + TC AG + CC AG + TT AG + TC AG + CC
14 38 17 69 5 23 5 33
GG + TT GG + TC GG + CC GG + TT GG + TC GG + CC
4 8 5 17 5 12 11 28
Total 22 53 26 101 10 46 17 73
No statistical differences between Control and Study groups
Fig. 1 Representative gel of the polymorphism pattern resulting from the restriction with XbaI of amplified samples for the estrogen receptor
alpha. Samples with one band only indicate a wild profile (~ 1300 pb, eg., lane 12), whereas samples with three bands (~ 1300, ~ 900, and
~400pb, eg., lanes 2 and 5) and with two bands (~ 900 and ~400pb, eg., lanes 3 and 4) indicate the heterozygous and homozygous profiles for
mutation, respectively. The arrows point to the migration of each of the expected fragments. P, molecular weight standard (100 pb step ladder
– Promega)
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significant association between both polymorphism and
central precocious puberty.
Research into the mechanisms leading to precocious
puberty is necessary to prescribe an early and more effi-
cacious treatment. In the last decades, many researchers
have focused on the discovery of genetic markers for an
early diagnosis as well as on the development of new
and more effective therapies based on the biomarkers,
with the possible outcome of improved prognosis, that
is, an increase in height for the patient. Even though
there was no significant difference between the groups
in our study, perhaps due to the small sample or lack of
subjects with a family history of PP, continuing studies
with these polymorphisms are still a necessity before an
association with this disorder can be rejected. It should
be noted that the incidence of precocious puberty in the
population is small, approximately 20/10,000 girls [1],
making research slow and laborious. Therefore our study
has some limitations, such as the small sample. Also, we
found that the Xbal genotype distribution in control
group was not consistent with Hardy-Weinberg equilib-
rium. Perhaps, a confirmation of genotyping method
using a fraction of pregenotyped sample using a sequen-
cing randomly and concordant between the techniques
may decrease this problem.
Conclusion
The development of precocious puberty is not related
with estrogen receptor alpha gene polymorphisms (PvuII
and XbaI).
Additional files
Additional file 1: Polymorphism data. Description of data: The XBAl and
PvuII Polymorphism data of control and study (precocious puberty) were
on the additional file. (XLSX 37 kb)
Abbreviations
BMI: Body mass index; CPP: Central precocious puberty; ESR1: Gene of the
estrogen receptor α; PP: Precocious puberty; PvuII and XbaI: Reα gene
polymorphisms; Rea: Estrogen receptor alpha
Acknowledgements
Mary Flynn revised the manuscript.
Funding
This study was supported by FAPESP, CNPq and CAPES (Brasíla-Br).
Availability of data and materials
We included the database in the supplemental files.
Authors’ contributions
JMSJ, FSH - have made substantial contributions to conception and design,
or acquisition of data, or analysis and interpretation of data; have been
involved in drafting the manuscript or revising it critically for important
intellectual content; have given final approval of the version to be published;
and agree to be accountable for all aspects of the work in ensuring that
questions related to the accuracy or integrity of any part of the work are
appropriately investigated and resolved. ICES- have been involved in drafting
the manuscript or revising it critically for important intellectual content; have
given final approval of the version to be published; and agree to be
accountable for all aspects of the work in ensuring that questions related to
the accuracy or integrity of any part of the work are appropriately
investigated and resolved. LCA - have been involved in drafting the
manuscript or revising it critically for important intellectual content; have
given final approval of the version to be published; and agree to be
accountable for all aspects of the work in ensuring that questions related to
the accuracy or integrity of any part of the work are appropriately
investigated and resolved. ECAV - have been involved in drafting the
manuscript or revising it critically for important intellectual content; have given
final approval of the version to be published; and agree to be accountable for
all aspects of the work in ensuring that questions related to the accuracy or
integrity of any part of the work are appropriately investigated and resolved.
CNM- have made substantial contributions to conception and design, or
acquisition of data, or analysis and interpretation of data; have given final
approval of the version to be published; and agree to be accountable for all
aspects of the work in ensuring that questions related to the accuracy or
integrity of any part of the work are appropriately investigated and resolved.
KCC- have made substantial contributions to conception and design, or
acquisition of data, or analysis and interpretation of data; have given final
approval of the version to be published; and agree to be accountable for all
aspects of the work in ensuring that questions related to the accuracy or
integrity of any part of the work are appropriately investigated and resolved.
ECB- have been involved in drafting the manuscript or revising it critically for
important intellectual content; have given final approval of the version to be
published; and agree to be accountable for all aspects of the work in ensuring
that questions related to the accuracy or integrity of any part of the work are
appropriately investigated and resolved. JMSJ- have made substantial
contributions to conception and design, or acquisition of data, or analysis and
interpretation of data; have been involved in drafting the manuscript or revising
it critically for important intellectual content; have given final approval of the
version to be published; and agree to be accountable for all aspects of the
work in ensuring that questions related to the accuracy or integrity of any part
of the work are appropriately investigated and resolved. All authors read and
approved the final manuscript.
Ethics approval and consent to participate
All participants or legal guardian gave us the written informed consent to
participate in the study. Also, this study was approval by the ethical
committee of Federal University of São Paulo (#2028/09).
Fig. 2 Representative gel of the polymorphism pattern resulting from the restriction with PvuIIof amplified samples for the estrogen receptor
alpha. Samples with one band only indicate a wild profile (~ 1300 pb, eg., lane 12), whereas samples with three bands (~ 1300, ~ 900, and
~400pb, eg., lanes 3 and 5) and with two bands (~ 900 and ~400pb, eg., lanes 7 and 9) indicate the heterozygous and homozygous profiles for
mutation, respectively. The arrows point to the migration of each of the expected fragments
Soares-Jr et al. BMC Medical Genetics  (2018) 19:84 Page 5 of 6
Consent for publication
The manuscript does not have any specific details, images or videos from
each patient. Therefore, we did not include the consent to publish of
patients.
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Disciplina de Ginecologia, Departamento de Obstetrícia e Ginecologia,
Hospital das Clínicas, Faculdade de Medicina da USP, Av. Dr. Eneas de
Carvalho Aguiar, 255 - Predio do Instituto Central, 10 andar, sala 10167, São
Paulo 05403-000, Brazil. 2Department of Gynecology, UNIFESP, São Paulo,
Brazil. 3Discipline of Science Design and Writing - Medical School of ABC, São
Paulo, Brazil.
Received: 18 September 2017 Accepted: 17 April 2018
References
1. Teilmann G, Pedersen CB, Jensen TK, et al. Prevalence and incidence of
precocious pubertal development in Denmark: an epidemiologic study
based on national registries. Pediatrics. 2005;116:1323.
2. Carvalho MACR, Sá MFS. Puberdade Precoce. In: Viana LC, Geber S, Martins
M, editors. Ginecologia. Rio de Janeiro: MEDSI; 1998. p. 471–80.
3. Chemaitilly W, Trivin C, Adan L, Gall V, Sainte-Rose C, Brauner R. Central
precocious puberty: clinical and laboratory features. Clin Endocrinol. 2001;
54(3):289–94.
4. Brito VN, Latronico AC, Arnhold IJ, Mendonça BB. Update on the etiology,
diagnosis and therapeutic management of sexual precocity. Arq Bras
Endocrinol Metabol. 2008;52:18–31.
5. Parent AS, Teilmann G, Juul A, Skakkebaek NE, Toppari J, Bourguignon JP.
The timing of normal puberty and the age limits of sexual precocity:
variations around the world, secular trends, and changes after migration.
Endocr Rev. 2003;24:668–93.
6. Navarro VM, Castellano JM, García-Galiano D, Tena-Sempere M.
Neuroendocrine factors in the initiation of puberty: the emergent role of
kisspeptin. Rev Endocr Metab Disord. 2007;8:11–20.
7. Clarkson J, Herbison AE. Development of GABA and glutamate signaling at the
GnRH neuron in relation to puberty. Mol Cell Endocrinol. 2006;254-5:32–8.
8. Fujita M, Tase T, Kakugawa Y, Hoshi S, Nishino Y, Nagase S, Ito K, Niikura H,
Yaegashi N, Minami Y. Smoking, earlier menarche and low parity as
independent risk factors for gynecologic cancers in Japanese: a case-control
study. Tohoku J Exp Med. 2008;216(4):297–307.
9. Rasier G, Matagne V, Parent AS, Gerard A, Lebrethon MC, Bourguignon JP.
Estradiol and dichlorodiphenyltrichloroethane (DDT) administration in
infantile female rats: similar stimulation of gonadotropin-releasing hormone
(GnRH) secretion in vitro and sexual maturation in vivo through different
receptor mechanisms. In: Proceedings of the 87th Annual Meeting of the
Endocrine Society, vol. 190. San Diego: Endocrine Society; 2005.
10. Gorai I, Tanaka K, Inada M, Morinaga H, Uchiyama Y, Kikuchi R, Chaki O,
Hirahara F. Estrogen-metabolizing gene polymorphisms, but not estrogen
receptor-alpha gene polymorphisms, are associated with the onset of
menarche in healthy postmenopausal Japanese women. J Clin Endocrinol
Metab. 2003;88(2):799–803.
11. Moenter SM, Defazio RA, Straume M, Nunemaker CS. Steroid regulation of
GnRH neurons. Ann N Y Acad Sci. 2003;1007:143–52.
12. Rønnekleiv OK, Bosch MA, Zhang C. 17β-oestradiol regulation of
gonadotrophin-releasing hormone neuronal excitability. J Neuroendocrinol.
2012;24:122–30.
13. Castagnoli A, Maestri I, Bernardi F, Del Senno L. PvuII RFLP inside the human
estrogen receptor gene. Nucleic Acids Res. 1987;15:866.
14. Zuppan PJ, Hall JM, Ponglikitmongkol M, Spielman R, King MC.
Polimorphisms at the Estrogen Receptor (ESR) locus and linkage
relationships on chromosome 6q. Cytogenet Cell Genet. 1989;51:1116.
15. Slattery ML, Curtin K, Giuliano AR, Sweeney C, Baumgartner R, Edwards S,
Wolff RK, Baumgartner KB, Byers T. Active and passive smoking, IL6, ESR1,
and breast cancer risk. Breast Cancer Res Treat. 2008;109(1):101–11.
16. Souza MA, Fonseca AM, Bagnoli VR, de Barros N, Franzolin SO, Carvalho KC,
Soares-Jr JM, Baracat EC. Polymorphisms of estrogen receptor-α gene in
Brazilian women with high breast density after menopause. Gynecol
Endocrinol. 2013;29(8):771–4.
17. Souza MA, Fonseca Ade M, Bagnoli VR, Barros N, Neves EM, Moraes SD,
Hortense VH, Soares JM, Baracat EC. The expression of the estrogen
receptor in obese patients with high breast density (HBD). Gynecol
Endocrinol. 2014;30(1):78–80.
18. Luo Y, Liu Q, Lei X, Wen Y, Yang YL, Zhang R, Hu MY. Association of
estrogen receptor gene polymorphisms with human precocious puberty: a
systematic review and meta-analysis. Gynecol Endocrinol. 2015;31(7):516–21.
19. Stavrou I, Zois C, Ioannidis JP, Tsatsoulis A. Association of polymorphisms of
the oestrogen receptor alpha gene with the age of menarche. Hum
Reprod. 2002;17:1101–5.
20. Jarzabek-Bielecka G, Warchoł-Biedermann K, Sowińska E, Wachowiak-
Ochmańska K. Precocious puberty. Ginekol Pol. 2011;82(4):281–6.
21. Speroff L, Fritz MA. Abnormal puberty and growth problems. Clinical
gynecologicendocrinology and infertility. Philadelphia: Lippincott Williams &
Wilkins; 2011. p. 361–99.
22. De Vries L, Kauschansky A, Shohat M, Phillip M. Familial central precocious
puberty suggests autossomal dominant inheritance. J Clin Endocrinol
Metab. 2004;89:1794–800.
23. Okatani Y, Morioka N, Wakatsuki A. Changes in nocturnal melatonin
secretion in perimenopausal women: correlation with endogenous estrogen
concentrations. J Pineal Res. 2000;28:111–8.
24. Plant TM, Shahab M. Neuroendocrine mechanisms that delay and initiate
puberty in higher primates. Physiol Behav. 2002;77(4–5):717–22.
25. Teles MG, Bianco SD, Brito VN, Trarbach EB, Kuohung W, Xu S, Seminara SB,
Mendonca BB, Kaiser UB, Latronico AC. A GPR54-activating mutation in a
patient with central precocious puberty. N Engl J Med. 2008;358(7):709–15.
26. Brandi ML, Becherini L, Gennari L, Racchi M, Bianchetti A, Nacmias B, Sorbi S,
Mecocci P, Senin U, Govoni S. Association of the estrogen receptor α gene
polymorphisms with sporadic Alzheimer's disease. Biochemical and
Biophysical Res Communications. 1999;265:335–8.
27. Massart F, Becherini L, Gennari L, Facchini V, Genazzani AR, Brandi ML.
Genotype distribution of estrogen receptor α gene polymorphisms in Italian
women with surgical uterine leiomyomas. Fertil Steril. 2001;75:567–70.
28. Tanaka Y, Sasaki M, Kaneuchi M. Polymorphisms of estrogen receptor alpha
in prostate cancer. Mol Carcinog. 2003;37:202–8.
29. Parl FF, Cavener DR, Dupont WD. Genomic DNA analysis of the estrogen
receptor gene in breast cancer. Breast Cancer Res Treat. 1989;14(1):57–64.
30. Lee HS, Park HK, Kim KH, Ko JH, Kim YJ, Yi KH, Hwang JS. Estrogen receptor
α gene analysis in girls with central precocious puberty. J Pediatr Endocrinol
Metab. 2013;26:645–9.
Soares-Jr et al. BMC Medical Genetics  (2018) 19:84 Page 6 of 6
